Accueil > Actualité
Actualite financiere : Actualite bourse

Sensorion: Stifel reiterates buy rating, TP E1.50

( - On Tuesday, Stifel reiterated its Buy recommendation on and E1.
50 target price for Sensorion shares, saying that it is more optimistic about the chances of success for its drug candidate SENS-501.

Looking back on the recent American Society of Gene and Cell Therapy (ASGCT) conference, the broker believes that the data presented by other laboratories (Regeneron, Refreshgene) on this occasion proved rather encouraging.

Competitors' clinical results continue to pile up, and while we're eager to discover Sensorion's initial findings, the arrival of favorable data and the fact that the drug candidates are close together make us confident, Stifel analysts say.

SENS-501 is a gene therapy program developed with a view to restoring hearing in patients carrying mutations linked to otoferlin deficiency.

In light of this information, Stifel says it has raised its chances of success for the product from 25% to 35%.

Copyright (c) 2024 All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.